@article{Kissling_E-2022_87496,
title = {Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021},
author = {Kissling, E. and Hooiveld, M. and Martínez-Baz, I. and Mazagatos, C. and William, N. and Vilcu, A. and Kooijman, M. and Ilić, M. and Domegan, L. and Machado, A. and de Lusignan, S. and Lazar, M. and Meijer, A. and Brytting, M. and Casado, I. and Larrauri, A. and Murray, J. and Behillil, S. and de Gier, B. and Mlinarić, I. and O'Donnell, J. and Rodrigues, A. and Tsang, R. and Timnea, O. and de Lange, M. and Riess, M. and Castilla, J. and Pozo, F. and Hamilton, M. and Falchi, A. and Knol, M. and Filipović, S. and Dunford, L. and Guiomar, R. and Cogdale, J. and Cherciu, C. and Jansen, T. and Enkirch, T. and Basile, L. and Connell, J. and Gomez, V. and Martin, V. and Bacci, S. and Rose, A. and Celentano, L. and Valenciano, M. and teams, I.},
month = {may},
year = {2022},
abstract = {Coronavirus disease (COVID-19) has caused considerable morbidity and mortality with more than 66 million cases and 1.2 million deaths reported in the World Health Organization European Region as at 5 September 2021. The highly transmissible Delta variant (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.617.2 and the AY sublineages) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominated over the Alpha variant (B.1.1.7) in Europe from July 2021 onwards and accounted for more than 99% of sequenced samples in weeks 35–36 in 2021. From mid-March 2021, four COVID-19 vaccines were authorised in the European Union by the European Medicines Agency: two mRNA vaccines (Comirnaty and Spikevax) and two adenoviral vector vaccines (Vaxzevria and COVID-19 Vaccine Janssen). Before the circulation of the Delta variant, randomised controlled trials indicated a high efficacy for these vaccines. Observational post-authorisation studies in Europe are therefore important to measure the effectiveness of the different COVID-19 vaccines against the currently circulating Delta variant.},
volume = {27},
issue = {21},
journal = {Eurosurveillance},
publisher = {European Centre for Disease Prevention and Control},
url = {https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104},
}
